Immunex Gets FDA Approval to Market Novantrone as MS Treatment

Immunex ( IMNX) received Food and Drug Administration approval to market Novantrone as a treatment for certain forms of multiple sclerosis.

Novantrone is currently marketed, in combination with corticosteroids, to treat pain in patients with advanced hormone-refractory prostate cancer and for an initial therapy of acute nonlymphocytic leukemia.

The FDA approval allows Immunex to promote Novantrone as a treatment for secondary progressive multiple sclerosis.

Shares of Immunex recently traded up $1.25, or 3.3%, to $38.88 in Nasdaq in midday trading.

More from Stocks

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever

Finding Stocks Right for You: Cramer's 'Mad Money' Recap (Friday 8/25/18)

Finding Stocks Right for You: Cramer's 'Mad Money' Recap (Friday 8/25/18)

Flashback Friday: Amazon, Chip Stocks, Memorial Day

Flashback Friday: Amazon, Chip Stocks, Memorial Day

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain